Below is a bibliography of Travere’s peer-reviewed manuscripts in reverse chronological order. For more information, including poster presentations, and upcoming medical congress activity, please visit Medical Affairs.



Jain M, Shah M, Thakker KM, et al. Estimating prevalence of classical homocystinuria in the United States using Optum’s de-identified market clarity data. Molecular Genetics and Metabolism Reports. 2024 Jun.

Kohan DE,  Bedard PW,  Jenkinson C, Hendry B,  Komers R. Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney diseaseClin Sci (Lond) 5 June 2024; 138 (11): 645–662. doi:

Campbell KN, Gesualdo L, Murphy E, et al. Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open Label Extension: Long-Term Efficacy and Safety. Kidney Medicine 2024 Article In Press.

Reily C, Moldoveanu Z, Pramparo T, et al. Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy. Am J Physiol Renal Physiol. 2024 Mar 21.

Nagasawa H, Ueda S, Suzuki H, et al. Sparsentan is Superior to Losartan in the gddY Mouse Model of IgA Nephropathy. Nephrol Dial Transplant. 2024; gfae021.

Lerma EV, Thakker KM, Bensink ME, et al. Kidney Failure Events, Cardiovascular Disease Events and All-Cause Mortality in Immunoglobulin A Nephropathy Patients in a Real-World Database. Kidney360. 2024; Epub ahead of print.

Trachtman H, Radhakrishnan J, Rheault MN, et al. Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study. Kidney Int Rep. 2024; In Press Journal Pre-Proof.

Bensink ME, Goldschmidt D, Zhou ZY, Wang K, Lieblich R, Bunke MC. Kidney Failure Attributed to Immunoglobulin A Nephropathy: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden. Kidney Med. 2024; 6(2);100759.

Bensink ME, Goldschmidt D, Zhou Z-Yi, et al. Kidney Failure Attributed to Focal Segmental Glomerulosclerosis: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden. Kidney Med.2024;6(2):100760.

Patel NK, Chen K-F, Chen S-C, et al. Physiologically-based pharmacokinetic model of sparsentan to evaluate drug-drug interaction potential. CPT Pharmacometrics Syst Pharmacol. 2024;13(2):317-329.



Rovin BH, Barratt J, Heerspink HJL, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet 2023; published online Nov 3. doi: 10.1016/S0140-6736(23)02302-4.

Rheault MN, Alpers CE, Barratt J, et al. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. Epub ahead of print. N Engl J Med. 2023 Nov 3. doi: 10.1056/NEJMoa2308550.

Trachtman H, Diva U, Murphy E, et al. Implications of complete proteinuria remission at any time in focal segmental glomerulosclerosis: sparsentan DUET trial. Kidney Int Rep. 2023;Aug 3 [Epub ahead of print].

Caster DJ, Abner CW, Walker PD, et al. Clinicopathological characteristics of adult IgA nephropathy in the United States. Kidney Int Rep. 2023;Jun 27 [Epub ahead of print].

Lerma EV, Bensink ME, Thakker KM, et al. Impact of proteinuria and kidney function decline on health care costs and resource utilization in adults with IgA nephropathy in the United States: a retrospective analysis. Kidney Med. 2023;5(9):100693.

Heerspink HJL, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. 2023;401(10388):1584-1594.

Cosgrove D, Gratton MA, Madison J, et al. Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice. J Pathol. 2023;260(3):353-364.

Wada R, Kleijn HJ, Zhang L, et al. Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis. CPT Pharmacometrics Syst Pharmacol. 2023;12(8):1080-1092.

Chen S-C, Cai D, Winnett C, et al. Effect of multiple doses of sparsentan on the single-dose pharmacokinetics of dapagliflozin: an open-label drug–drug interaction study in healthy adults. Clin Pharmacol Drug Dev. 2023;12(5):535-541.

Jhaveri KD, Bensink ME, Bunke M, et al. Humanistic and economic burden of IgA nephropathy: systematic literature reviews and narrative synthesis. Pharmacoecon Open. 2023;Apr 27 [Epub ahead of print].

Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727-738.

Barratt J, Rovin B, Wong MG, et al. IgA nephropathy patient baseline characteristics in the sparsentan PROTECT study. Kidney Int Rep. 2023;8(5):1043-1056.

Pramparo T, Steiner RD, Rodems S, Jenkinson C. Allelic prevalence and geographic distribution of cerebrotendinous xanthomatosis, Orphanet J Rare Dis. 2023 Jan 17;18(1):13. doi: 10.1186/s13023-022-02578-1.



Mikel C, Goldfarb DS, Ponte A, Steigelman K, Latyshev S, Goldfarb D. Accurate 24-h urine cystine quantification for patients on cystine-binding thiol drugs. Urolithiasis. 2022 Dec;50(6):721-727. doi: 10.1007/s00240-022-01364-9. Epub 2022 Oct 6.

Caster DJ, Magalhaes B, Pennese N, et al. Efficacy and safety of immunosuppressive therapy in primary focal segmental glomerulosclerosis: a systematic review and meta-analysis. Kidney Med. 2022;4:100501.

Floege J, Barratt J, Coppo R, et al. International physicians Delphi survey: managing patients with IgA nephropathy. Kidney Int Rep. 2022;7(9):2076-2080.

Campbell KN, Pennese N, Zaffalon A, et al. Efficacy and safety of ACE inhibitor and angiotensin receptor blocker therapies in primary focal segmental glomerulosclerosis treatment: a systematic review and meta-analysis. Kidney Med. 2022;4(5):100457.



Sanchez P, Farkhondeh A, Pavlinov I, Baumgaertel K, Rodems S, Zheng W. Therapeutics development for Alagille syndrome. Front Pharmacol. 2021 Aug 23;12:704586. doi: 10.3389/fphar.2021.704586. eCollection 2021.

Brooks BM, Pradhan M, Cheng YS, Gorshkov K, Farkhondeh A, Chen CZ, Beers J, Liu C, Baumgaertel K, Rodems S, Zheng W. Generation of an induced pluripotent stem cell line (TRNDi031-A) from a patient with Alagille syndrome type 1 carrying a heterozygous p. C312X (c. 936 T > A) mutation in JAGGED-1. Stem Cell Res. 2021 Jul;54:102447. doi: 10.1016/j.scr.2021.102447. Epub 2021 Jun 24.

Zhu W, Cheng YS, Xu M, Farkhondeh A, Beers J, Zou J, Liu C, Baumgaertel K, Rodems S, Zheng W. Generation of Alagille syndrome derived induced pluripotent stem cell line carrying heterozygous mutation in the JAGGED-1 gene at splicing site (Chr20: 10,629,709C>A) before exon 11. Stem Cell Res. 2021 May;53:102366. doi: 10.1016/j.scr.2021.102366. Epub 2021 Apr 27.



Komers R, Diva U, Inrig JK, et al. Study design of the phase 3 sparsentan versus irbesartan (DUPLEX) study in patients with focal segmental glomerulosclerosis. Kidney Int Rep. 2020;5(4):494-502.

Trachtman H, Hogan JJ, Tesar V, et al. dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, treatment of focal segmental glomerulosclerosis, treatment of IgA nephropathy. Drugs Future. 2020;45(2):79-98



Barratt J, Rovin B, Diva U, et al. Implementing the kidney health initiative surrogate efficacy endpoint in patients with IgA nephropathy (the PROTECT trial). Kidney Int Rep. 2019;4(11):1633-1637.

Modersitzki F, Goldfarb DS, Goldstein RL, Sur RL, Penniston KL. Assessment of health-related quality of life in patients with cystinuria on tiopronin therapy. Urolithiasis. 2020 Aug;48(4):313-320. doi: 10.1007/s00240-019-01174-6. Epub 2019 Dec 13.



Trachtman H, Nelson P, Adler S, et al. DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol. 2018;29(11):2745-2754.



Komers R, Gipson DS, Nelson P, et al. Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: randomized, controlled trial design (DUET). Kidney Int Rep. 2017;2(4):654-664.



Komers R, Plotkin H. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease. Am J Physiol Regul Integr Comp Physiol. 2016;310(10):R877-R884.



RET246  07/2023